Dynavax Technologies Net Income 2010-2021 | DVAX

Dynavax Technologies net income from 2010 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Dynavax Technologies Annual Net Income
(Millions of US $)
2021 $72
2020 $-75
2019 $-156
2018 $-159
2017 $-95
2016 $-112
2015 $-107
2014 $-91
2013 $-75
2012 $-70
2011 $-49
2010 $-57
2009 $-31
Dynavax Technologies Quarterly Net Income
(Millions of US $)
2021-12-31 $95
2021-09-30 $-28
2021-06-30 $4
2021-03-31 $1
2020-12-31 $-15
2020-09-30 $4
2020-06-30 $-52
2020-03-31 $-13
2019-12-31 $-37
2019-09-30 $-37
2019-06-30 $-43
2019-03-31 $-40
2018-12-31 $-40
2018-09-30 $-41
2018-06-30 $-39
2018-03-31 $-39
2017-12-31 $-27
2017-09-30 $-22
2017-06-30 $-20
2017-03-31 $-25
2016-12-31 $-22
2016-09-30 $-35
2016-06-30 $-29
2016-03-31 $-27
2015-12-31 $-27
2015-09-30 $-30
2015-06-30 $-24
2015-03-31 $-26
2014-12-31 $-22
2014-09-30 $-30
2014-06-30 $-25
2014-03-31 $-14
2013-12-31 $-22
2013-09-30 $-16
2013-06-30 $-17
2013-03-31 $-21
2012-12-31 $-21
2012-09-30 $-18
2012-06-30 $-15
2012-03-31 $-17
2011-12-31 $-4
2011-09-30 $-15
2011-06-30 $-11
2011-03-31 $-18
2010-12-31 $-15
2010-09-30 $-5
2010-06-30 $-28
2010-03-31 $-9
2009-12-31 $-30
2009-09-30 $-10
2009-06-30 $4
2009-03-31 $5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.240B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.746B 9.96
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.525B 16.61
Biohaven Pharmaceutical Holding (BHVN) United States $9.916B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.438B 6.15
Arcus Biosciences (RCUS) United States $1.419B 35.98
Myovant Sciences (MYOV) United Kingdom $0.944B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.492B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.309B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.085B 0.00